Telix Pharmaceuticals Ltd (STU:T3X)
€ 14.31 -0.3 (-2.05%) Market Cap: 4.89 Bil Enterprise Value: 4.84 Bil PE Ratio: 162.08 PB Ratio: 19.98 GF Score: 75/100

Telix Pharmaceuticals Ltd at JPMorgan Healthcare Conference Transcript

Jan 11, 2023 / 07:00PM GMT
Seth Schwartz

Good morning, everyone. My name is Seth Schwartz, and I lead JPMorgan's health care investment banking practice in Australia. Great honor and privilege this morning to welcome and introduce Chris Behrenbruch, CEO and Managing Director of Telix Pharmaceuticals.

Christian P. Behrenbruch
Telix Pharmaceuticals Limited - Co-Founder, Group MD, CEO & Executive Director

Thanks very much, Seth, and it's a pleasure to be here to tell you about our very exciting company. I'm just going to get the slides up here.

Great. So just skipping over the customary disclaimer. So just a bit of a high-level overview of Telix, so we're a therapeutics company but with a strong precision medicine or theranostics bent. We have a commercial stage portfolio in diagnostic imaging. And particularly, we just launched our first product in prostate cancer, and I'm going to be talking a little bit more about that. We also just had a readout, a very nice strong readout on our Phase III trial in renal cancer. And so those are our 2 sort of commercial stage assets.

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot